Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kura Oncology, Inc.NASDAQ: KURA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $73.33M (cash outflow) rose 27.7% year over year, behind the +62.0% change in trailing-twelve-month net income. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at +27.1% a year.
Context
- Net income amounted to 412.9% of revenue in FY2025, up 90.1 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$287.81M (+3.3%) for the fiscal year ending Dec 2026, a slowdown from the +60.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$73.33M-9.5% QoQ
- Last fiscal yearDec 2025
- -$278.67M+60.2% YoY
- LTMMar 2026
- -$294.57M+62.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.7% | +19.2% | -8.5 pp |
| 1 year | +60.2% | +3.3% | -56.9 pp |
| 3-year CAGR | +27.1% | -9.2% | -36.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (278.67M) USD
- Year-over-year change
- -60.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (278.67M) | -60.2% |
| FY2024 | 2024-12-31 | (173.98M) | -14.0% |
| FY2023 | 2023-12-31 | (152.63M) | -12.4% |
| FY2022 | 2022-12-31 | (135.84M) | -4.1% |
| FY2021 | 2021-12-31 | (130.47M) | — |
Net Income vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 net income of $294.57M is the 4th largest of the 11 companies compared; the peer median is $87.93M.
- Its year-over-year change of +62.0% is the 5th highest of 11, against a peer median of +36.9%.
- Net income amounts to 411.2% of revenue for KURA, versus a peer median of 116.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $466.88M | +1212.4% | — | 77.5% | |
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $294.57M | +62.0% | +27.1% | 411.2% | |
| LTM Mar 2026 | $243.25M | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $154.1M | +1029.3% | +3264.4% | — |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $131.11M | +36.0% | +29.4% | — | |
| LTM Mar 2026 | $44.76M | -8.4% | +5.8% | 8526.1% | |
| LTM Sep 2026 | $35.76M | +37.8% | -13.4% | — | |
| Peer median (excluding KURA) | $87.93M | +36.9% | +18.9% | 116.8% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | (7.46M) |
| Deferred Income Tax | 4.6M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.58M | 26.32M | 28.08M | 33.9M | 37.11M |
| Change in Working Capital | (3.22M) | (2.98M) | 7.82M | 286.17M | 184.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (6.74M) |
| Inventory | 0 | 0 | 0 | 0 | (413K) |
| Accounts Payables | (2.52M) | (802K) | 10.33M | 15.2M | 4.5M |
| Other Working Capital | (706K) | (2.18M) | (2.51M) | 270.97M | 187.1M |
| Other Non-Cash Items | 399K | 1.68M | (8.94M) | (12.62M) | 515K |
| Operating Cash Flow | (104.55M) | (110.06M) | (124.82M) | 134.32M | (64.06M) |
| Capital Expenditures | (1.15M) | (626K) | (168K) | (472K) | (6.64M) |
| Acquisitions (Net) | 125.69K | (33.25K) | 0 | 0 | 0 |
| Purchases of Investments | (445.66M) | (270.66M) | (409.82M) | (659.05M) | (761.59M) |
| Sales of Investments | 319.97M | 303.91M | 425.55M | 557.93M | 755.13M |
| Other Investing Activities | (125.69K) | 33.25K | 0 | 0 | 0 |
| Investing Cash Flow | (126.84M) | 32.63M | 15.56M | (101.59M) | (13.1M) |
| Debt Repayment | (7.25M) | 10M | 0 | 0 | 0 |
| Common Stock Issued | 4.43M | 24.72M | 93.58M | 145.81M | 1.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (611K) | 3.84M | 1.21M | 8.6M | 0 |
| Financing Cash Flow | (3.44M) | 38.57M | 94.78M | 154.42M | 1.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (234.82M) | (38.87M) | (14.48M) | 187.14M | (75.36M) |
| Free Cash Flow | (105.7M) | (110.69M) | (124.99M) | 133.85M | (70.7M) |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.